Theriva Biologics Inc

Research Theriva Biologics Inc (TOVX) on Bullrun: market cap USD 11.93M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerTOVX
• ExchangeNYSE MKT
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 11.93M
• Financial periodFY2025
• Net income-USD 23.74M
• Free cash flow-USD 16.70M

Valuation Snapshot

latest market cap is USD 11.93M.

About Theriva Biologics Inc

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors;

Frequently asked questions

What is Theriva Biologics Inc's market cap?

Theriva Biologics Inc's market capitalization is USD 11.93M.

What does Theriva Biologics Inc do?

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States.